| Aggregate Evidence Quality . | Grade C . |
|---|---|
| Benefits | Lower risk of childhood target organ damage, lower risk of adulthood HTN and CVD |
| Risk, harm, cost | Risk of drug adverse effects and polypharmacy |
| Benefit–harm assessment | Preponderance of benefit |
| Intentional vagueness | None |
| Role of patient preferences | Patient may have preference for nonpharmacologic or pharmacologic treatment |
| Exclusions | None |
| Strength | Moderate recommendation |
| Key references | 11,66,103,104,416–418 |
| Aggregate Evidence Quality . | Grade C . |
|---|---|
| Benefits | Lower risk of childhood target organ damage, lower risk of adulthood HTN and CVD |
| Risk, harm, cost | Risk of drug adverse effects and polypharmacy |
| Benefit–harm assessment | Preponderance of benefit |
| Intentional vagueness | None |
| Role of patient preferences | Patient may have preference for nonpharmacologic or pharmacologic treatment |
| Exclusions | None |
| Strength | Moderate recommendation |
| Key references | 11,66,103,104,416–418 |